Shattuck Labs (NASDAQ:STTK) Given “Hold” Rating at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Shattuck Labs (NASDAQ:STTK) in a research note published on Thursday morning,Benzinga reports.

Other analysts have also recently issued reports about the company. HC Wainwright cut Shattuck Labs from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 1st. Citigroup cut Shattuck Labs from a “buy” rating to a “neutral” rating and cut their target price for the stock from $8.00 to $2.00 in a research note on Wednesday, October 2nd. Finally, Evercore ISI raised Shattuck Labs to a “strong-buy” rating in a research note on Wednesday, October 2nd. Four research analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $8.67.

Shattuck Labs Trading Down 5.1 %

Shares of NASDAQ:STTK traded down $0.07 on Thursday, reaching $1.30. 142,798 shares of the company traded hands, compared to its average volume of 450,598. The business’s 50-day simple moving average is $2.13 and its 200 day simple moving average is $4.34. Shattuck Labs has a 52 week low of $1.07 and a 52 week high of $11.76. The stock has a market capitalization of $62.05 million, a P/E ratio of -0.74 and a beta of 1.85.

Insider Buying and Selling

In other Shattuck Labs news, CEO Taylor Schreiber acquired 36,500 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was purchased at an average price of $1.21 per share, with a total value of $44,165.00. Following the transaction, the chief executive officer now directly owns 71,002 shares in the company, valued at approximately $85,912.42. The trade was a 105.79 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 10.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Shattuck Labs

A number of hedge funds have recently modified their holdings of STTK. SG Americas Securities LLC boosted its holdings in Shattuck Labs by 4.8% in the 1st quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after buying an additional 1,788 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in Shattuck Labs in the 1st quarter worth $174,000. Vanguard Group Inc. boosted its holdings in Shattuck Labs by 38.2% in the 1st quarter. Vanguard Group Inc. now owns 1,819,926 shares of the company’s stock worth $16,270,000 after buying an additional 502,860 shares during the period. Virtu Financial LLC bought a new position in Shattuck Labs in the 1st quarter worth $113,000. Finally, Bank of New York Mellon Corp boosted its holdings in Shattuck Labs by 209.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 222,034 shares of the company’s stock worth $857,000 after buying an additional 150,340 shares during the period. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.